| Literature DB >> 32631904 |
Hong Lou1, Joseph F Boland1, Edmundo Torres-Gonzalez2, Anaseidy Albanez3, Weiyin Zhou1, Mia K Steinberg1, Lena Diaw2, Jason Mitchell1, David Roberson1, Michael Cullen1, Lisa Garland1, Sara Bass1, Robert D Burk4, Meredith Yeager1, Nicolas Wentzensen5, Mark Schiffman5, Enrique Alvirez Freites6,7, Eduardo Gharzouzi8, Lisa Mirabello5, Michael Dean9.
Abstract
Human papillomavirus (HPV) 16 displays substantial sequence variation; four HPV16 lineages (A, B, C, and D) have been described as well as multiple sublineages. To identify molecular events associated with HPV16 carcinogenesis, we evaluated viral variation, the integration of HPV16, and somatic mutation in 96 cervical cancer samples from Guatemala. A total of 65% (62/96) of the samples had integrated HPV16 sequences and integration was associated with an earlier age of diagnosis and premenopausal disease. HPV16 integration sites were broadly distributed in the genome, but in one tumor, HPV16 integrated into the promoter of the IFN regulatory factor 4 (IRF4) gene, which plays an important role in the regulation of the IFN response to viral infection. The HPV16 D2 and D3 sublineages were found in 23% and 30% of the tumors, respectively, and were significantly associated with adenocarcinoma. D2-positive tumors had a higher rate of integration, earlier age of diagnosis, and a lower rate of somatic mutation, whereas D3-positive tumors were less likely to integrate, had later age of diagnosis, and exhibited a higher rate of somatic mutation. In conclusion, Guatemalan cervical tumors have a high frequency of very high-risk HPV16 D2 and D3 sublineages harboring distinct histology, which may help guide future therapeutic strategies to target the tumor and reduce recurrence. SIGNIFICANCE: This study details the biological and molecular properties of the most pathogenic forms of HPV16, the cause of the majority of cervical cancers. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32631904 PMCID: PMC7501218 DOI: 10.1158/0008-5472.CAN-20-0029
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701